FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.97 USD
0.01 (0.201%)
TSVT Financial Statements
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Total Revenue
2.93M
13.53M
8.97M
12.44M
Cost of Revenue
8.84M
5.77M
3.45M
6.61M
Gross Profit
-5.92M
7.77M
5.51M
5.83M
Operating Expenses
17.35M
21.71M
24.19M
54.48M
Research and Development
8.65M
8.32M
16.01M
41.82M
Selling, General & Administrative Expenses
8.52M
12.88M
9.86M
12.66M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
0
0
0
0
Other Expenses
172k
503k
0
646k
Operating Income
-23.27M
-13.94M
-20.36M
-48.65M
Total Other Income/Expenses Net
3.75M
4.01M
45.23M
-4.02M
Income Before Tax
-19.52M
-9.93M
24.88M
-52.67M
Income Tax
0
0
0
2.06M
Net Income
-19.52M
-9.93M
24.88M
-52.67M
Basic EPS
-0.37
-0.19
0.48
-1.01
EPS Diluted
-0.37
-0.19
0.45
-1.01
Basic Average Shares
52.33M
52.26M
52.19M
52.07M
Diluted Average Shares
52.33M
52.26M
55.01M
52.07M
EBITDA
-21.44M
-11.78M
-18.25M
-46.55M
Retained Earning Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Retained Earnings (Previous Year)
-548.94M
-539.01M
-563.89M
-511.22M
Net Income
-19.52M
-9.93M
24.88M
-52.67M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-568.46M
-548.94M
-539.01M
-563.89M
Other Distributions
-19.52M
-9.93M
24.88M
-52.67M
PPE Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Gross PPE
238.15M
240.96M
247.18M
253.55M
Annual Depreciation
1.66M
1.66M
1.68M
2.11M
Capital Expenditure
0
-34k
-61k
-612k
Net PPE
236.5M
239.34M
245.56M
252.06M
Intangible and Goodwill Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
